IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$73.26 USD
+1.13 (1.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.35 +0.09 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
ITCI 73.26 +1.13(1.57%)
Will ITCI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ITCI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITCI
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
ITCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
Other News for ITCI
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
3 Biotech Stocks With Skyrocketing Potential: April 2024
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
Intra-Cellular price target raised by $7 at Canaccord, here's why
Buy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder Market